Back to top Open menu arrow
Download Reprints
Sections
METHODS RESULTS DISCUSSION CONCLUSION Article Information Clinical Points
The Journal of Clinical Psychiatry The Journal of Clinical Psychiatry

The Journal of
Clinical Psychiatry
Access icon

Review Article June 5, 2024

Cognitive Effects of Electroconvulsive Therapy in Schizophrenia: A Systematic Review

Sophie R. Vaccarino, MD, MSc; Anthony L. Vaccarino, PhD

J Clin Psychiatry. 2024;85(2):23r15045

Abstract

Objective: To determine the objective cognitive effects of electroconvulsive therapy (ECT) in treatment-resistant schizophrenia (TRS).

Data Sources: A database search of MEDLINE, PsycINFO, and Embase was conducted on September 22, 2022, using the search terms “schizophrenia” and “electroconvulsive therapy.” The search was limited to the articles published from 1985 to present, in English, and human studies.

Study Selection: A total of 4293 articles were identified. After screening by title and full text, 17 articles met eligibility criteria. Controlled, open-label, and retrospective studies of acute, maintenance, or continuation ECT were included. An objective cognitive measure(s) had to be the primary or secondary outcome of the study, with no other interventions administered, besides standard-of-care treatment (ie, antipsychotics).

Data Extraction: Data regarding the study design, type of ECT provided, cognitive outcome measures, and change in cognitive performance pre- to post-ECT were extracted. Results are presented as a narrative review.

Results: Overall, ECT was not associated with any significant cognitive deficits in participants with TRS across the domains of global cognition, attention, language, visuospatial function, and executive function. Findings for immediate effects on memory were equivocal, but the majority of studies found no change or an improvement in memory after treatment.

Conclusions: The current evidence supports the conclusion that ECT does not have negative long-term effects on cognition among patients with TRS. Larger, sham-controlled trials are needed to support these conclusions. All studies in this review assessed ECT adjunct to antipsychotics; therefore, the cognitive effects of ECT independent of antipsychotics remain unclear.

J Clin Psychiatry 2024;85(2):23r15045

Author affiliations are listed at the end of this article.

Continue Reading...

Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.

Subscribe Now

Already a member? Login

Purchase PDF for $40

Members enjoy free PDF downloads on all articles. Join today

  1. Dickinson D, Harvey PD. Systemic hypotheses for generalized cognitive deficits in schizophrenia: a new take on an old problem. Schizophr Bull. 2009;35(2):403–414. PubMed CrossRef
  2. Bowie CR, Harvey PD. Cognitive deficits and functional outcome in schizophrenia. Neuropsychiatr Dis Treat. 2006;2(4):531–536. PubMed CrossRef
  3. Heaton RK, Gladsjo JA, Palmer BW, et al. Stability and course of neuropsychological deficits in schizophrenia. Arch Gen Psychiatry. 2001;58(1):24–32. PubMed CrossRef
  4. Green MF, Kern RS, Braff DL, et al. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the “right stuff”. Schizophr Bull. 2000;26(1):119–136. PubMed CrossRef
  5. Rajji TK, Miranda D, Mulsant BH. Cognition, function, and disability in patients with schizophrenia: a review of longitudinal studies. Can J Psychiatry. 2014;59(1):13–17. PubMed CrossRef
  6. American Psychiatric Association. The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia. 3rd ed. American Psychiatric Association Publishing; 2020.
  7. Remington G, Addington D, Honer W, et al. Guidelines for the pharmacotherapy of schizophrenia in adults. Can J Psychiatry. 2017;62(9):604–616. PubMed CrossRef
  8. Keefe RSE, Bilder RM, Davis SM, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiatry. 2007;64(6):633–647. PubMed CrossRef
  9. MacKenzie NE, Kowalchuk C, Agarwal SM, et al. Antipsychotics, metabolic adverse effects, and cognitive function in schizophrenia. Front Psychiatry. 2018;9:622. PubMed CrossRef
  10. Siskind D, Orr S, Sinha S, et al. Rates of treatment-resistant schizophrenia from first-episode cohorts: systematic review and meta-analysis. Br J Psychiatry. 2022;220(3):115–120. PubMed CrossRef
  11. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951–962. PubMed CrossRef
  12. Siskind D, Siskind V, Kisely S. Clozapine response rates among people with treatment-resistant schizophrenia: data from a systematic review and meta analysis. Can J Psychiatry. 2017;62(11):772–777. PubMed CrossRef
  13. Kane JM, Agid O, Baldwin ML, et al. Clinical guidance on the identification and management of treatment-resistant schizophrenia. J Clin Psychiatry. 2019;80(2):18com12123. PubMed CrossRef
  14. Howes OD, McCutcheon R, Agid O, et al. Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry. 2017;174(3):216–229. PubMed CrossRef
  15. Lally J, Tully J, Robertson D, et al. Augmentation of clozapine with electroconvulsive therapy in treatment resistant schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2016;171(1–3):215–224. PubMed CrossRef
  16. Sanghani SN, Petrides G, Kellner CH. Electroconvulsive therapy (ECT) in schizophrenia: a review of recent literature. Curr Opin Psychiatry. 2018;31(3):213–222. PubMed CrossRef
  17. Yeh TC, Correll CU, Yang FC, et al. Pharmacological and nonpharmacological augmentation treatments for clozapine-resistant schizophrenia: a systematic review and network meta-analysis with normalized entropy assessment. Asian J Psychiatr. 2023;79:103375. PubMed CrossRef
  18. Baldinger P, Lotan A, Frey R, et al. Neurotransmitters and electroconvulsive therapy. J ECT. 2014;30(2):116–121. PubMed CrossRef
  19. Lyden H, Espinoza RT, Pirnia T, et al. Electroconvulsive therapy mediates neuroplasticity of white matter microstructure in major depression. Transl Psychiatry. 2014;4(4):e380. PubMed CrossRef
  20. Bouckaert F, Sienaert P, Obbels J, et al. ECT: its brain enabling effects A review of electroconvulsive therapy–induced structural brain plasticity. J ECT. 2014;30(2):143–151. PubMed CrossRef
  21. Jiang Y, Duan M, He H, et al. Structural and functional MRI brain changes in patients with schizophrenia following electroconvulsive therapy: a systematic review. Curr Neuropharmacol. 2022;20(6):1241–1252. PubMed CrossRef
  22. Moon S-Y, Kim M, Lho SK, et al. Systematic review of the neural effect of electroconvulsive therapy in patients with schizophrenia: Hippocampus and insula as the key regions of Modulation. Psychiatry Investig. 2021;18(6):486–499. PubMed CrossRef
  23. Fink M. Meduna and the origins of convulsive therapy. Am J Psychiatry. 1984;141(9):1034–1041. PubMed CrossRef
  24. Leiknes KA, Jarosh-von Schweder L, Høie B. Contemporary use and practice of electroconvulsive therapy worldwide. Brain Behav. 2012;2(3):283–344. PubMed CrossRef
  25. American Psychiatric Association. The Practice of ECT: Recommendations for Treatment, Training and Privileging. 2nd ed. American Psychiatric Press; 2001.
  26. National Institute for Clinical Excellence. Guidance on the use of electroconvulsive therapy. In: Technology Appraisal 59;2003.
  27. Scott AIF. The ECT Handbook: The Third Report of the Royal College of Psychiatrists’ Special Committee of ECT. RCPsych Publications; 2005.
  28. Chakrabarti S, Grover S, Rajagopal R. Electroconvulsive therapy: a review of knowledge, experience and attitudes of patients concerning the treatment. World J Biol Psychiatry. 2010;11(3):525–537. PubMed CrossRef
  29. Rose D, Fleischmann P, Wykes T, et al. Patients’ perspectives on electroconvulsive therapy: systematic review. BMJ. 2003;326(7403):1363. PubMed CrossRef
  30. Semkovska M, McLoughlin DM. Objective cognitive performance associated with electroconvulsive therapy for depression: a systematic review and meta-analysis. Biol Psychiatry. 2010;68(6):568–577. PubMed CrossRef
  31. Sackeim HA, Prudic J, Fuller R, et al. The cognitive effects of electroconvulsive therapy in community settings. Neuropsychopharmacology. 2007;32(1):244–254. PubMed CrossRef
  32. Ward HB, Szabo ST, Rakesh G. Maintenance ECT in schizophrenia: a systematic review. Psychiatry Res. 2018;264:131–142. PubMed CrossRef
  33. Ali SA, Mathur N, Malhotra AK, et al. Electroconvulsive therapy and schizophrenia: a systematic review. Mol Neuropsychiatry. 2019;5(2):75–83. PubMed
  34. Zheng W, Tong G, Ungvari GS, et al. Memory impairment following electroconvulsive therapy in Chinese patients with schizophrenia: meta-analysis of randomized controlled trials. Perspect Psychiatr Care. 2018;54(2):107–114. PubMed CrossRef
  35. Runck B. NIMH report. Consensus panel backs cautious use of ECT for severe disorders. Hosp Community Psychiatry. 1985;36(9):943–946. PubMed CrossRef
  36. Guyatt GH, Oxman AD, Schünemann HJ, et al. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol. 2011;64(4):380–382. PubMed CrossRef
  37. Meader N, King K, Llewellyn A, et al. A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation. Syst Rev. 2014;3:82. PubMed CrossRef
  38. Jiang J, Li J, Xu Y, et al. Magnetic seizure therapy compared to electroconvulsive therapy for schizophrenia: a randomized controlled trial. Front Psychiatry. 2021;12:770647. PubMed CrossRef
  39. Stryjer R, Ophir D, Bar F, et al. Rivastigmine treatment for the prevention of electroconvulsive therapy-induced memory deficits in patients with schizophrenia. Clin Neuropharmacol. 2012;35(4):161–164. PubMed CrossRef
  40. Petrides G, Malur C, Braga RJ, et al. Electroconvulsive therapy augmentation in clozapine-resistant schizophrenia: a prospective, randomized study. Am J Psychiatry. 2015;172(1):52–58. PubMed CrossRef
  41. Yang Y, Cheng X, Xu Q, et al. The maintenance of modified electroconvulsive therapy combined with risperidone is better than risperidone alone in preventing relapse of schizophrenia and improving cognitive function. Arq Neuropsiquiatr. 2016;74(10):823–828. PubMed CrossRef
  42. Bansod A, Sonavane SS, Shah NB, et al. A randomized, nonblind, naturalistic comparison of efficacy and cognitive outcomes with right unilateral, bifrontal, and bitemporal electroconvulsive therapy in schizophrenia. J ECT. 2018;34(1):26–30. PubMed
  43. Chan CYW, Abdin E, Seow E, et al. Clinical effectiveness and speed of response of electroconvulsive therapy in treatment-resistant schizophrenia. Psychiatry Clin Neurosci. 2019;73(7):416–422. PubMed CrossRef
  44. Chanpattana W. Maintenance ECT in treatment-resistant schizophrenia. J Med Assoc Thai. 2000;83(6):657–662. PubMed
  45. Chanpattana W, Kramer BA. Acute and maintenance ECT with flupenthixol in refractory schizophrenia: sustained improvements in psychopathology, quality of life, and social outcomes. Schizophr Res. 2003;63(1–2):189–193. PubMed CrossRef
  46. Davarinejad O, Hendesi K, Shahi H, et al. A pilot study on daily intensive ECT over 8 days improved positive and negative symptoms and general psychopathology of patients with treatment-resistant schizophrenia up to 4 weeks after treatment. Neuropsychobiology. 2019;77(2):83–91. PubMed CrossRef
  47. Liu Y, Jia LN, Wu H, et al. Adjuvant electroconvulsive therapy with antipsychotics is associated with improvement in auditory mismatch negativity in schizophrenia. Psychiatry Res. 2022;311:114484. PubMed CrossRef
  48. Mishra BR, Agrawal K, Biswas T, et al. Comparison of acute followed by maintenance ECT vs clozapine on psychopathology and regional cerebral blood flow in treatment-resistant schizophrenia: a randomized controlled trial. Schizophr Bull. 2022;48(4):814–825. PubMed CrossRef
  49. Simsek GG, Zincir S, Gulec H, et al. Do ictal EEG characteristics predict treatment outcomes in schizophrenic patients undergoing electroconvulsive therapy? Nord J Psychiatry. 2015;69(6):466–471. PubMed CrossRef
  50. Tan XW, Lim KWK, Martin D, et al. Effects of electroconvulsive therapy on cognition and quality of life in schizophrenia. Ann Acad Med Singap. 2022;51(7):400–408. PubMed CrossRef
  51. Vuksan Ćusa B, Klepac N, Jakšić N, et al. The effects of electroconvulsive therapy augmentation of antipsychotic treatment on cognitive functions in patients with treatment-resistant schizophrenia. J ECT. 2018;34(1):31–34. PubMed
  52. Wysokinski A, Dzienniak M, Kloszewska I. Assessment of cognitive performance using CNS vital signs after electroconvulsive treatment of schizophrenia. J ECT. 2014;30(1):e5–e6. PubMed
  53. Niemansburg SL, van Delden JJM, Dhert WJA, et al. Reconsidering the ethics of sham interventions in an era of emerging technologies. Surgery. 2015;157(4):801–810. PubMed CrossRef
  54. Kim JH, Youn T, Choi JG, et al. Combination of electroconvulsive therapy and clozapine in treatment-resistant schizophrenia. Psychiatry Investig. 2018;15(8):829–835. PubMed CrossRef
  55. Pawelczyk A, Kolodziej-Kowalska E, Pawelczyk T, et al. Is there a decline in cognitive functions after combined electroconvulsive therapy and antipsychotic therapy in treatment-refractory schizophrenia? J Nerv Ment Dis. 2015;203(3):182–186. PubMed
  56. Li P, Jing RX, Zhao RJ, et al. Electroconvulsive therapy-induced brain functional connectivity predicts therapeutic efficacy in patients with schizophrenia: a multivariate pattern recognition study. NPJ Schizophr. 2017;3:21. PubMed CrossRef
  57. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–198. PubMed
  58. Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695–699. PubMed CrossRef
  59. Randolph C, Tierney MC, Mohr E, et al. The repeatable Battery for the assessment of neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol. 1998;20(3):310–319. PubMed CrossRef
  60. Kennedy JL, Altar CA, Taylor DL, et al. The social and economic burden of treatment-resistant schizophrenia: a systematic literature review. Int Clin Psychopharmacol. 2014;29(2):63–76. PubMed CrossRef
  61. Correll CU, Brevig T, Brain C. Patient characteristics, burden and pharmacotherapy of treatment-resistant schizophrenia: results from a survey of 204 US psychiatrists. BMC Psychiatry. 2019;19(1):362. PubMed CrossRef
  62. Millgate E, Hide O, Lawrie SM, et al. Neuropsychological differences between treatment-resistant and treatment-responsive schizophrenia: a meta-analysis. Psychol Med. 2022;52(1):1–13.
  63. Kumar S, Mulsant BH, Liu AY, et al. Systematic review of cognitive effects of electroconvulsive therapy in late-life depression. Am J Geriatr Psychiatry. 2016;24(7):547–565. PubMed CrossRef
  64. UK ECT Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet. 2003;361(9360):799–808. PubMed CrossRef
  65. Lomas M, Rickard V, Milton F, et al. Electroconvulsive therapy related autobiographical amnesia: a review and case report. Cogn Neuropsychiatry. 2021;26(2):107–121. PubMed CrossRef
  66. Lappin JM, Davies K, O’Donnell M, et al. Underuse of recommended treatments among people living with treatment-resistant psychosis. Front Psychiatry. 2022;13:987468. PubMed CrossRef
  67. Wang W, Pu C, Jiang J, et al. Efficacy and safety of treating patients with refractory schizophrenia with antipsychotic medication and adjunctive electroconvulsive therapy: a systematic review and meta-analysis. Shanghai Arch Psychiatry. 2015;27(4):206–219. PubMed CrossRef
  68. Grover S, Sahoo S, Rabha A, et al. ECT in schizophrenia: a review of the evidence. Acta Neuropsychiatr. 2019;31(3):115–127. PubMed CrossRef
  69. Dowman J, Patel A, Rajput K. Electroconvulsive therapy: attitudes and misconceptions. J ECT. 2005;21(2):84–87. PubMed CrossRef
  70. Maroney M. An update on current treatment strategies and emerging agents for the management of schizophrenia. Am J Manag Care. 2020;26(3 suppl):S55–S61. PubMed CrossRef
  71. Ventura J, Thames AD, Wood RC, et al. Disorganization and reality distortion in schizophrenia: a meta-analysis of the relationship between positive symptoms and neurocognitive deficits. Schizophr Res. 2010;121(1–3):1–14. PubMed CrossRef
  72. Cicek M, McCall WV, Yao Z, et al. Is there evidence that stimulus parameters and electrode placement affect the cognitive side effects of electroconvulsive therapy in patients with schizophrenia and schizoaffective disorder? a systematic review. J ECT. 2021;37(2):133–139. PubMed CrossRef
Purchase PDF for $40

Members enjoy free PDF downloads on all articles. Join today

Save Save

Share Share

Cite Cite

Vol 85 • 2024 • Number 3

Read the Current Issue

Editorial

Focus on Women’s Mental Health: Twenty Years and Counting

Original Research

Esmethadone in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants

Commentary

Can Our Collective Experiences As Clinicians Improve Mental Health Care?

Original Research

Prescription Opioid Use Disorder in US Adults Reporting Prescription Opioid Use

Original Research

Symptomatic Disorders Comorbid with Borderline Personality Disorder Over Time

Original Research

Aripiprazole Lauroxil Initiation Regimens
View current Issue

Celebrating
85 Years

Read the Journal of Clinical Psychiatry

Subscribe to read
more articles

Subscribe